🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Glenn Liu

University of Wisconsin Carbone Cancer Center

ORCID: 0000-0002-9819-1911
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)”.

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-004198
N/A
1.2DataRank · unranked
52 citations

Jens C. Eickhoff, Ellen Wargowski, Laura E. Johnson, Christos E. Kyriakopoulos, Hamid Emamekhoo +4 more

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-008067
N/A
0.937DataRank · unranked
36 citations

Hamid Emamekhoo, Jens C. Eickhoff, Christos E. Kyriakopoulos, Ellen Wargowski, Tommaso P Tonelli +3 more

Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer

Human Vaccines & Immunotherapeutics(2024)10.1080/21645515.2024.2395680
N/A
0.408DataRank · unranked
10 citations

Jens C. Eickhoff, Laura E. Johnson, Glenn Liu, Douglas G. McNeel, Tommaso P Tonelli

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps267
N/A
0.165DataRank · unranked
2 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507
N/A
0.104DataRank · unranked
1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5098
N/A
0DataRank · unranked
3 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps273
N/A
0DataRank · unranked
2 citations

Christos E. Kyriakopoulos, Glenn Liu, Douglas G. McNeel, Hamid Emamekhoo

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5118
N/A
0DataRank · unranked
1 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps402
N/A
0DataRank · unranked
0 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer

European Urology Oncology(2024)10.1016/j.euo.2024.11.009
N/A
0DataRank · unranked
13 citations

Yi Ren, Meghan Tierney, Trevor J. Royce, Rikiya Yamashita, Danielle Croucher +13 more

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.162
N/A
0DataRank · unranked
18 citations

Victoria Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den, Gerhardt Attard +10 more